A Comparison of Reboxetine and Amitryptilline in the Treatment of Fibromyalgia Syndrome with Co-morbid Depressive Symptoms: An Open-label Preliminary Study

Konuk, Numan; Ortancil, Özgür; Bostanci, Bora; Kıran, Sibel; Sapmaz, Perihan

doi:10.1080/10177833.2010.11790631

Cited by 9 publications

(6 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study by Sumpton and Moulin [2], the authors found that tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors (SNRIs) (duloxetine and milnacipran), and α2-δ ligands (gabapentin and pregabalin) are effective in reducing FM-associated pain by ≥30%. Amitriptyline was also associated with improvement in pain fatigue, sleep, and quality of life [50][51][52].…”

Section: Pharmacological Treatmentmentioning

confidence: 98%

Review of Fibromyalgia (FM) Syndrome Treatments

Cohen-Biton

Buskila

Nissanholtz-Gannot

2022

IJERPH

View full text Add to dashboard Cite

Background: Fibromyalgia (FM) is a disease characterized by widespread musculoskeletal chronic pain that impairs the patient’s quality of life and is considered a somatization disorder. The symptoms of the disease also affect the patient mentally, mainly since invisible pain is the only thing that indicates its existence. A typical symptom that characterizes FM patients is the lack of acceptance of the disease since its pathophysiology is not elucidated, hence the deficiencies in its management, or rather, cognitively, the belief that there is no disease to manage. The current paper aims to shed light on the new treatment methods at a holistic level, that is, cognitive, physical, and pharmacological therapies. Method: A literature review was carried out that discusses treatment methods that help alleviate the pain, accept it, and manage the symptoms of the disease. Results: FM symptoms can be treated by taking a broad view of treatment that will include a response to the mind through pain management, response to the body through physical activity, and response to the pain through pharmacological treatment. Conclusions: Today, there is an evolutionary view that accepts FM and chronic pain diseases as syndromes in which the pain is the disease; therefore, the response to this disease can be applied through three channels: physical, bodily, and mental.

show abstract

Section: Pharmacological Treatmentmentioning

confidence: 98%

Review of Fibromyalgia (FM) Syndrome Treatments

Cohen-Biton

Buskila

Nissanholtz-Gannot

2022

IJERPH

View full text Add to dashboard Cite

show abstract

“…Amitriptyline was found to reduce the FIQ questionnaire results from baseline to endpoint by over 30% [48][49][50]. It was found to improve pain, fatigue, sleep, and quality of life [11].…”

Section: Tricyclic Antidepressants (Tcas) Although Differentmentioning

confidence: 99%

Current and Emerging Pharmacotherapy for Fibromyalgia

Tzadok

Ablin

2020

Pain Research and Management

View full text Add to dashboard Cite

Introduction. Fibromyalgia syndrome (FMS) is a pain disorder with an estimated prevalence of 1–5%. It is associated with a variety of somatic and psychological disorders. Its exact pathogenesis is still unclear but is involved with neural oversensitization and decreased conditioned pain modulation (CPM), combined with cognitive dysfunction, memory impairment, and altered information processing. Connectivity between brain areas involved in pain processing, alertness, and cognition is increased in the syndrome, making its pharmacologic therapy complex. Only three drugs, pregabalin, duloxetine, and milnacipran are currently FDA-approved for FM treatment, but many other agents have been tested over the years, with varying efficacy. Areas Covered. The purpose of this review is to summarize current clinical experience with different pharmacologic treatments used for fibromyalgia and introduce future perspectives in developing therapies. Expert Opinion. Future insights into the fields of cannabinoid and opioid research, as well as an integrative approach towards the incorporation of genetics and functional imaging combined with additional fields of research relevant towards the study of complex CNS disorders, are likely to lead to new developments of novel tailor-made treatments for FMS patients.

show abstract

“…Amitriptyline had the greatest association with reduced sleep disturbances and fatigue and improved quality of life. Additionally, amitriptyline reduced patient FIQ scores by 30% [ 29 , 31 , 35 , 42 ]. Alternatively, duloxetine had the greatest improvement in pain and depression [ 35 ].…”

Section: Managementmentioning

confidence: 99%

“…Additionally, amitriptyline reduced patient FIQ scores by 30% [ 29 , 31 , 35 , 42 ]. Alternatively, duloxetine had the greatest improvement in pain and depression [ 35 ]. Milnacipran was less efficacious but showed significant improvement in pain and fatigue [ 30 ].…”

Section: Managementmentioning

confidence: 99%

Management of Fibromyalgia: An Update

Jones,

Asaad,

Patel

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Fibromyalgia, a chronic pain condition marked by abnormal pain processing, impacts a significant part of the population, leading to reduced quality of life and function. Hallmark symptoms include widespread persistent pain, sleep disturbances, fatigue, cognitive dysfunction, and mood changes. Through this updated review, we aim to contribute to the evolving understanding and management of fibromyalgia, offering insights into the diverse tools available to improve the lives of those affected by this challenging condition. Management begins with educating patients to ultimately relieve them of unnecessary testing and provide reassurance. Treatment emphasizes a comprehensive approach, combining nonpharmacological interventions such as aforementioned education, exercise, and psychotherapy, alongside pharmacologic management—namely duloxetine, milnacipran, pregabalin, and amitriptyline—which have consistent benefits for a range of symptoms across the spectrum of fibromyalgia. Notably, drugs like nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen are generally not recommended due to limited efficacy and associated risks. Lastly, a variety of other medications have shown promise, including NMDA-receptor antagonists, naltrexone, and cannabinoids; however, they should be used with caution due to a small amount of evidence and potential for adverse effects.

show abstract

A Comparison of Reboxetine and Amitryptilline in the Treatment of Fibromyalgia Syndrome with Co-morbid Depressive Symptoms: An Open-label Preliminary Study

Cited by 9 publications

References 42 publications

Review of Fibromyalgia (FM) Syndrome Treatments

Review of Fibromyalgia (FM) Syndrome Treatments

Current and Emerging Pharmacotherapy for Fibromyalgia

Management of Fibromyalgia: An Update

Contact Info

Product

Resources

About